Bruin Biometrics LLC, a medical technology platform company that provides digital solutions for pressure injury prevention and management to health systems in the U.S. and U.K., announced it has...

Attendees at this year's American College of Foot and Ankle Surgeons Annual Meeting in Phoenix, Ariz. will be the first to see Medline UNITE's new Synthetic Ligament Augmentation implant. The...

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera...

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the...

PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new...

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen...

Medit a global leader in digital dentistry, has launched its latest All-on-X solution, Medit SmartX. This innovative solution empowers implant clinicians to fully leverage the potential of the...

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M...

Vilcek Foundation Prizes for Creative Promise in Biomedical Science are being accepted now through June 9, 2025. These $50,000 prizes are given each year to three early- to mid-career immigrant...

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of FZ002 for C. difficile...

Currax Pharmaceuticals LLC a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion HCl), announced the publication of...